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ABSTRACT 
Colorectal cancer (CRC) is the third most common form of cancer in the world. 5-
Fluorouracil (5-FU) belongs to the fluoropyrimidine-type of drugs and is commonly used in 
the treatment of several solid tumors. It has become the mainstay of CRC treatment at stage 
III and high risk stage II, either alone or in combination with other drugs. Primary drug 
effects include both DNA damage and RNA stress but the relative importance of each 
triggering points remains elusive. 
In Paper I we investigated the signaling cascade leading to 5-FU-induced cell death in the 
colon carcinoma cell line HCT116 in more detail; especially, with respect to the early 
response and ensuing apoptosis. Upon 5-FU treatment, the death-inducing signaling 
complex (DISC) was formed on the plasma membrane and this process was facilitated by 
p53. Increase in intracellular levels of Ca
2+
, at least partially via L-type channels, was an 
early response which led to phosphorylation of at least three p53 serine sites (S15, S33, 
S37) upstream of caspase-8. Mutational analysis concluded that S15 phosphorylation was 
necessary for the processing of caspase-8 and PARP. Analyses using small molecule 
inhibitors indicated that Ca
2+
-dependent calmodulin served as an intermediate factor 
preceding p53 phospho-activation. 
Altogether, obtained results present the evidence for a novel apoptotic signaling mechanism 
induced by 5-FU, dependent on extracellular Ca
2+
, involving DR-DISC and regulated by 
p53, p53 phosphorylations and calmodulin. 
In Paper II we focused on cell death signaling pathways in 5-FU-stressed p53
-/-
 cells. Using 
the human colon carcinoma parental cell line HCT116 and its variant lacking p53, we found 
that the cell death per se induced by 5-FU is independent of p53. However, in the absence 
of the tumor suppressor, the apoptotic response is delayed. In addition, the lack of p53 was 
associated with the formation of reactive oxygen species (ROS) in mitochondria which 
resulted in necrotic characteristics. Co-treatment with zVAD-fmk and 5-FU revealed that 
DNA damage, reflected in phosphorylation of the histone H2AX (γH2AX), is a 
consequence rather than a cause of apoptosis. Finally, our data suggested that silencing of 
PARP-1 function may be used as an approach to selectively sensitize p53-deficient tumor 
cells to 5-FU. 
In Paper III we examined the possible crosstalk between apoptosis and autophagy upon 5-
FU treatment. In contrast to cells in which apoptosis was blocked, either at the DISC or the 
mitochondrial level, p53 deficiency was associated with deregulation of autophagy in 
response to 5-FU. Disruption of lysosomal function with chloroquine (CQ) caused a 
profound reduction in the appearance of apoptotic markers, as a consequence of death 
receptor (DR) accumulation in lysosomes and autophagosomes. 
Since RNAi targeting of critical regulators of autophagy or inhibition of lysosomal 
cathepsins reversed apoptosis in different manners, it is unlikely that autophagy per se, but 
rather correct receptor transport is an important factor for 5-FU-induced cell death. 
Interestingly, apoptosis activated via TRAIL, the cognate ligand for DR5, remained 
unaffected in the presence of CQ, indicating that 5-FU activates the receptor by a discrete 
mechanism. Through depletion of membrane cholesterol or inhibition of cholesterol 
transport, the cytotoxicity of 5-FU was drastically reduced, thereby supporting the idea that 
correct trafficking of the receptor is important for 5-FU-mediated elimination of cells. 
In conclusion, this study indicates a novel chemotherapy-induced mechanism for activation 
of DR5, which may have important ramifications on research conducted in the apoptosis 
and tumor treatment field. 
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1. GENERAL INTRODUCTION 
1.1 Cancer 
Cancer is one of the leading causes of death worldwide and the prevalence of the disease is 
increasing
1
. Genetic susceptibility, mutations, environmental factors, diet and life style 
behaviors have been associated with the risk of cancer development, but a detailed 
description of how and why cancer is formed remains to be established. In an attempt to 
describe the distinguishing properties that enable tumor growth and metastatic 
dissemination, Hanahan and Weinberg introduced the “ten hallmarks of cancer” in the 
second edition of the “millennium review”. These are sustaining proliferative signaling, 
resisting cell death, evading growth suppressors, inducing angiogenesis, enabling 
replicative immortality, activating invasion, metastasis, deregulating cellular energetics, 
avoiding immune destruction, genome instability and mutation and tumor promoting 
inflammation
2
. 
1.2 Modes of cell death 
Depending on the triggering stimulus and the microenvironment, cells can die by several 
mechanisms including apoptosis, necrosis and autophagy. The Nomenclature Committee on 
Cell Death (NCCD) proposed recommendations to classify types of cell death according to 
their well-defined morphological characteristics and biochemical features
3-5
. Regulation of 
cell death pathways is important for embryonic development and maintenance of normal 
tissue homeostasis of adult organisms. In addition, dysregulation of cell death is associated 
with several diseases. It is therefore vital to investigate the mechanisms of cell death 
modalities in order to develop novel therapeutic approaches. 
1.2.1 Apoptosis 
Apoptosis is the first described and most studied mode of cell death
6
. Through this 
programmed elimination of damaged or unwanted cells, tissue homeostasis is maintained 
without invoking inflammation. Dysregulation of apoptosis has been implicated in the 
development of several diseases, including cancer, autoimmune diseases, and 
neurodegenerative disorders
7,8
. Eventually, an improved comprehension of key molecular 
components and apoptosis regulatory mechanisms can help to develop targeted therapeutic 
strategies. 
Apoptosis is executed by a family of cysteinyl aspartate proteinases, caspases, which cleave 
their specific substrates next to an aspartate residue during the caspase signaling cascade
9
. 
 10 
They are synthesized as inactive zymogens containing an N-terminal prodomain followed 
by the appearance of a p20 (large) and a p10 (small) subunit
10
. Caspases may be classified 
into two subgroups on the basis of the length of their prodomain: 1) Initiator caspases 
containing long prodomains; 2) Effector caspases containing short prodomains. 
Long prodomains of initiator caspases harbor either a death effector domain (DED) 
(caspase-8 and -10) or a caspase-associated recruitment domain (CARD) (caspase-2 and -
9). Since initiator caspases require dimerization and autoproteolysis for their activation 
occurring in response to multiprotein complex formation, these domains mediate caspase-
interactions with adaptor molecules (such as Apaf-1, FADD and RAIDD)
11
. 
Effector caspases (caspase-3, -6 and -7) are characterized by the presence of a short 
prodomain and are expressed as inactive dimers which require cleavage by upstream 
caspases for their activation
12
. In consequence, they cleave multiple down-stream 
substrates, a process leading to the characteristic morphological features of apoptosis, such 
as cell membrane blebbing, cell shrinkage, chromatin condensation, and DNA 
fragmentation
13
. 
Various types of cellular stress (DNA damage, growth-factor deprivation) can activate 
apoptosis through two main signaling mechanisms: the extrinsic (death receptor-mediated) 
and the intrinsic (mitochondria-mediated) pathways. 
1.2.1.1 The extrinsic pathway 
The extrinsic apoptotic pathway is initiated by the binding of tumor necrosis factor (TNF) 
superfamily ligands to their cognate death receptors (DRs). DRs are type I transmembrane 
proteins, characterized by the presence of cysteine rich domains in their extracellular 
portion which mediate ligand binding
14
. Furthermore, the cytoplasmic region contains 
approximately 80 amino acids long death domains (DDs) which enable DRs to induce cell 
death through homotypic domain interactions
15-17
. At present six death receptors have been 
described: TNF-R1
18, 19
, FAS (CD95)
20,21
, DR4 (TRAIL-R1)
22
, DR5 (TRAIL-R2)
23-27
, DR3 
(TRAMP)
28-31
 and DR6
32
. TNF-R1 mainly controls inflammatory, prosurvival IKK/NF-κB 
or JNK/c-Jun pathways whereas DR3 controls noncanonical NF-κB signaling33-36. FAS, 
DR4 and DR5 are the main mediators of the extrinsic pathway. 
Most of the TNF superfamily ligands are synthesized as stable homotrimeric type II 
transmembrane proteins. The specific biophysical context of the ligand can determine the 
outcome of the intracellular signaling. For example, soluble TNFα activates the TNF-R1 
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mediated NF-κB pathway, whereas membrane-displayed TNFα activates the TNF-R1 
mediated extrinsic apoptotic pathway
37, 38
. 
1.2.1.1.1 DISC formation 
The binding of a homotrimeric death inducing ligand to its cognate homotrimeric DR 
results in further conformational change, clustering of multiple ligand-receptor complexes 
at the plasma membrane, and ultimately formation of a death-inducing signaling complex 
(DISC) (Fig. 1). Preassembly of DRs through their extracellular pre-ligand assembly 
domain (PLAD) is critical for ligand binding
39
. Ligation to DR results in recruitment of the 
adaptor protein FAS-associated death domain (FADD) by means of death domain (DD) 
interactions and in turn, recruitment of procaspase-8 to the DISC occurs through homotypic 
death effector domain (DED) interactions
40,41
. 
Caspase-8 predominantly exists as a monomeric cytoplasmic protein. After recruitment to 
the DISC, the monomers adapt a dimeric conformation which in turn triggers catalytic 
activity and autocleavage
42
. In addition to interdomain cleavage, which alone can activate 
executioner caspases, the activation of caspase-8 requires dimerization and further 
posttranslational modifications such as ubiquitination
43-45
. Active caspase-8 initiates the 
caspase cascade by cleaving downstream effector caspases such as caspases -3, -6 and -7
46-
48
. Once effector caspases are activated they cleave downstream substrates and thereby 
cause the characteristic biochemical and morphological hallmarks of apoptosis discussed 
above
49
. 
Besides FADD and caspase-8, the FLICE-like inhibitory protein (cFLIP) and caspase-10 
are also recruited to the DISC. Although caspase-10 is highly homologous to caspase-8 it 
cannot trigger apoptosis
50
. Its function in the DISC remains unknown. cFLIP is one of the 
major regulators of caspase-8 activation at the DISC level and has two main mRNA splice 
variants; cFLIPL and cFLIPS (long and short, respectively). Furthermore, cFLIP contains an 
N-terminal DED similar to the one of caspase-8 but the protein lacks a catalytic cysteine 
residue
51, 52
. Both cFLIP variants are capable to dimerize at the DISC either with itself or 
with caspase-8/-10
53, 54
. The role of cFLIP variants is controversial. It has been reported that 
these isoforms may inhibit or activate apoptosis depending on their expression levels and 
according to their formation of heterodimers with procaspase-8
53,55-57
. 
In TNFα-induced TNF-R1 activation a different adaptor molecule, the TNFR-associated 
death domain (TRADD), enables the recruitment of the DD containing TNF receptor-
associated factor 2 (TRAF2) and the additional signaling molecule receptor-interacting 
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protein 1 (RIP1) to form the TNF-R1 signaling complex (TNF-RSC) which results in 
activation of IKK/NF-κB or JNK/c-Jun pathways58. 
The FAS DISC was first described in 1995, yet the exact stoichiometry of DISC 
components was not clear at the time
59
. The conventional model suggests that one complex 
includes one ligand trimer, 2-3 FADD, 2-3 caspase-8 and/or cFLIP monomers. Recently it 
was proposed that one ligand-receptor trimer recruits one FADD molecule which in turn 
recruits 6 to 10 DED-containing proteins
41,60,61
. 
1.2.1.2 The intrinsic pathway 
The intrinsic apoptotic pathway is initiated by internal stimuli and activated on the 
mitochondrial level. Initiator signals include irradiation-induced DNA damage, 
chemotherapeutics, growth factor deprivation, oxidative stress as well as other stress 
stimuli
62
. The intrinsic pathway is controlled and regulated by the Bcl-2 gene family 
proteins which share structural Bcl-2 homology (BH) domains
63
. Depending on the number 
of BH domains, this family can be divided into three subgroups: BH1-4, BH1-3 and, BH3-
only. BH1-4 containing proteins (Bcl-2, Bcl-XL, Mcl-1) serve anti-apoptotic functions, 
whereas BH1-3 (Bax, Bak) and BH3-only proteins (Bid, Bad) serve pro-apoptotic 
functions
64,65
. 
Upon stress signals BH3-only proteins are activated. As a result, Bax and Bak are 
oligomerized and localized to the outer mitochondrial membrane (OMM) causing 
disruption of OMM
66
. Mitochondrial outer membrane permeabilization (MOMP) triggers 
the release of cytochrome c from the intermembrane space of mitochondria to the 
cytoplasm. Subsequently, cytosolic cytochrome c binds to the apoptosis protease-activating 
factor 1 (Apaf-1), causing its conformational change and together with procaspase-9, in 
presence of dATP, an intracellular high molecular weight complex known as the 
apoptosome is generated
67
. Procaspase-9 has a caspase-associated recruitment domain 
(CARD) which mediates its interaction with the CARD-containing adaptor protein Apaf-1. 
Through this interaction procaspase-9 is recruited to the apoptosome
68
. Finally, the 
proteolytic activity of caspase-9 leads to processing of caspase-3
69
. 
Although the initial phases are characterized by distinct features, extrinsic and intrinsic 
pathways converge in the activation of effector caspases (caspases -3, -6 and -7), which in 
turn target a broad spectrum of cellular proteins, thereby, predestining cells to irreversible 
cell death. 
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Based on the requirement of the mitochondrial pathway for apoptosis induced by DRs, cells 
can be divided into type I and type II. In type I cells, DR-mediated caspase-8 activation is 
adequate to induce apoptosis whereas in type II cells (like HCT116), less caspase-8 activity 
is generated and involvement of the intrinsic pathway is needed for efficient apoptosis to 
occur. In this case, caspase-8 cleaves the cytosolic BH3-interacting-domain death agonist 
(Bid). Myristoylation of cleaved Bid is followed by its activation and translocation to 
mitochondria to form truncated Bid (tBid), which triggers the cell intrinsic apoptotic 
pathway through MOMP, augmenting the activation of executioner caspases and 
committing the cell to death (Fig. 1)
70
. 
Finally, cell fragments or apoptotic bodies, generated from apoptotic cells, are recognized 
through “find me” signals by the cell surface receptors in phagocytes and rapidly cleared by 
“eat me” signals before loss of membrane integrity. Therefore, inflammation and 
autoimmune reactions can be avoided and tissue homeostasis can be maintained
71
. 
FIGURE 1. CD95L- and TRAIL- induced DISC formation and apoptosis induction. 
Walczak H
58
 Cold Spring Harb Perspec Biol 2013; 5: a008698, copyright Cold Spring Harbor Laboratory 
Press (reused and reprinted with the permission). 
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1.2.2 Necrosis 
Necrosis can occur during normal physiological processes or as a consequence of 
pathological conditions
72
. This process can also be induced by microbial infections, reactive 
oxygen species (ROS) or by inhibition of TNF- or FAS-induced apoptosis by pan-caspase 
inhibitors
73
. Hallmarks of necrosis are vacuole formation, cell swelling and loss of plasma 
membrane integrity, the latter which results in an uncontrolled release of the cellular 
content into the cell’s environment and consequent damage of surrounding cells, promoting 
an inflammatory response in the corresponding tissues
74
. 
1.2.3 Autophagy 
Autophagy or “self-eating” is both a survival and a cell death mechanism which occurs in 
lysosomes. The process of autophagy catalyzes the degradation and subsequent recycling of 
proteins and organelles in order to maintain cell and tissue homeostasis
75
. It can act as a 
survival mechanism during periods of nutrient stress to enable energy production
76
. The 
process can also be induced in response to oxidative stress or accumulation of misfolded 
proteins
77
. It is mediated and regulated by autophagy-related (ATG) proteins. Capturing of 
intracellular material in double membrane-structures termed as autophagosomes is followed 
by the fusion with lysosomes and further degradation of autophagosomal content
75
. The 
effect of autophagy in a disease situation is proposed to be dual since suppression as well as 
promotion of tumorigenesis has been reported
78
. 
1.2.4 Crosstalk between modes of cell death 
Depending on the stimulus and environmental factors a discrete cell death mechanism is 
often activated. Inhibition of the primarily preferred cell death mechanism, however, can 
lead to the activation of a secondary pathway. Although FAS, DR4 and DR5 primarily 
mediate extrinsic apoptosis, they can also induce alternative pathways when apoptosis is 
inhibited. In addition, TNF-R1, which mainly controls inflammatory, prosurvival pathways, 
can activate apoptosis when NF-κB activation is blocked. Apart from the capability to 
generate a complex in plasma membranes FAS/DR4/DR5 as well as TNF-R1/DR3 can 
form secondary complexes in the cytosol, referred to as complex II, when the respective 
formation of complex I is inhibited. These complexes trigger a secondary pathway; the 
DR4/DR5 complex II triggers survival pathways, whereas the TNF-RSC complex II 
mediates induction of necrosis or apoptosis (Fig. 2)
58
. 
Apoptosis and autophagy have been reported to act in synergy but also to counteract each 
other
79
. It seems that apoptosis and autophagy can act as co-partners, meaning that if one 
  15 
program is blocked, the other may become dominant. However, autophagy can inhibit 
apoptosis to promote cell survival
80
. Some of the hallmarks of autophagy can also be 
observed in cells which undergo necrosis
81
. Inhibition of caspases often fails to block cell 
death per se, but instead converts it from apoptosis to necrosis. Moreover, mitochondria can 
act as a switchboard in the regulation of several cell death modes, including autophagy, 
apoptosis and necrosis
81
. 
Altogether, even if the currently defined modes of cell death can be divided into subgroups 
according to their morphological and biological features, their potential crosstalk 
necessitates general consideration in any given experimental system. 
 
FIGURE 2. Comparison of CD95/TRAIL-R1/R2 and TNF-R1/DR3 signaling. 
Walczak H
58
 Cold Spring Harb Perspec Biol 2013; 5: a008698, copyright Cold Spring Harbor Laboratory 
Press (reused and reprinted with the permission). 
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2. INTRODUCTION TO THE STUDY 
2.1 Colorectal cancer 
Colorectal cancer (CRC), the third most common form of cancer in the world, is estimated 
to cause 12.8% of all cancer-related deaths in the European Union in 2016, killing 173,400 
individuals
82
. Its predicted death rate is the second highest of all cancers in men 
(16.2/100,000) and third highest in women (9.3/100,000), but these rates have dropped by 
4.6% and 7.0%, respectively, since 2011 due to improved screening strategies and early 
diagnosis
83
. According to the tumor-node-metastasis (TNM) system, CRC is classified into 
four distinct stages
84
. Depending on the stage, where I is reflecting the early onset and IV 
an advanced disease, the five-year relative survival of patients with CRC is ranging 
between 90.3 and 12.5%
85
. Metastasis remains the main cause of poor prognosis and 
mortality
86,87
. 
CRC is a heterogeneous disease with epigenetic changes and gene alterations in tumor 
suppressor and/or oncogenes. Since the presence or absence of these markers in many cases 
relate to treatment outcome they are currently evaluated for their prognostic and predictive 
values. 
2.1.1 Microsatellite instability (MSI) 
Due to the mutations in mismatch repair (MMR) genes such as MLH1, MSH2, MSH6 and 
PMS2, base-base mispairs in microsatellite regions cannot be repaired which in turn result 
in changes in the length of repetitive DNA nucleotide sequences. Depending on the 
frequency, MSI can be divided into three subclasses: microsatellite instability-low,-high 
and stable (MSI-L, MSI-H, MSS)
88
. Fifteen percent of CRCs harbor MSI and the 
prevalence in sporadic CRCs varies between 4-20% depending on the stage; 4% in stage 
IV, 12% in stage III and 20% in stage II
89,90
. The results from different studies have shown 
that patients with MMR-deficient tumors had a better prognosis compared to patients with 
an intact MMR
91-93
. 
2.1.2 CpG island methylator phenotype (CIMP) 
A tumor suppressor gene can be silenced via methylation of CG-rich domains referred to as 
CpG islands in their promoter regions leading to CIMP and carcinogenesis
94,95
. The global 
hypomethylation in CRC and adenomas attracted most of the attention in the early years of 
molecular research. However, the CIMP is also associated with CRCs characterized by 
methylation of the MLH1 gene that will further cause MSI
96-98
. Yet, since current data are 
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inconsistent, further studies are needed in order to evaluate the CIMP as a prognostic and a 
predictive marker
99,100
. 
2.1.3 Loss of heterozygosity (LOH) 
Genomic loss of one of the alleles in tumor cells is termed loss of heterozygosity (LOH) 
and occurs in 70% of all CRCs analyzed
101,102
. LOH on chromosome 5q occurs as an early 
event during the tumor transition stage. LOH on 18q and on 17p, on the other hand, occur 
during later tumor stages. These loci are corresponding to the localization of adenomatous 
polyposis coli (APC), deleted in colon cancer (DCC) and p53 genes, indicating their 
important role in tumor progression
103,104
. Currently, the association between LOH status 
and survival or treatment outcome is elusive
105-108
. 
2.1.4. Other common mutations 
Somatic mutations in the APC tumor suppressor gene cause dysregulations in cell 
migration, β-catenin-dependent Wnt signaling and apoptosis, and account for 70-80% of 
sporadic CRCs 
109-111
. Furthermore, mutations in genes in the Wnt pathway such as 
CTNNB1, AXIN1, AXIN2 and TCF4 have also been identified in CRC
112
. 
The RAS proteins are members of the guanosine-5’triphosphate (GTP)ase-binding protein 
family. (GTP)ase-binding proteins promote intracellular signaling downstream of the 
epidermal growth factor receptor (EGFR) associated with the mitogen-activated protein 
kinase (MAPK) signal transduction pathway. The Kirsten rat sarcoma viral oncogene 
(KRAS) gene is mutated in approximately 30-40% of all CRCs and 85-90% of these 
mutations occur in exon 2 (codons 12 and 13)
104,113,114
. Due to these mutations, the MAPK 
pathway is constantly activated, resulting in non-responsiveness to EGFR-targeting drugs 
such as cetuximab and panitumumab
115,116
. 
Phosphatidylinositide-3-kinases (PI3Ks) belong to a family of lipid kinases which control 
cell survival, proliferation and differentiation by binding to and phosphorylating the 
phosphatidylinositol (PI3P) intracellular signaling proteins. The phosphatidylinositol 3-
kinase catalytic subunit, PIK3CA, was reported to be mutated in 15-25% of all CRCs 
leading to activation of the PI3-K-AKT survival pathway and thus playing a critical role in 
CRC pathogenesis
114
. In addition, oncogenes such as NRAS, BRAF, EGFR, CDK8 and 
tumor suppressor genes such as PTEN, SMAD4, SMAD2, TGFβIIR are also mutated in 
CRC with variable frequencies
109,117
.  
The treatment strategies of CRCs are closely related to the stage of the disease. Further 
studies on identification of potential prognostic and predictive makers in CRC will help to 
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personalize the treatment by identifying the patients who will benefit from a particular drug 
and also, eventually, generate more targeted therapies. 
2.2 p53 
The p53 gene, also known as the guardian of the genome, is a tumor suppressor gene which 
contributes to several facets of cell homeostasis including DNA repair, cell proliferation 
and differentiation, cell death and survival pathways. Activation of p53 through DNA 
damage, aberrant growth signals or lesions caused by chemotherapeutics drugs leads to 
stabilization of the protein, DNA binding and expression of p53-targeted genes, 
consequently promoting cell death or cell cycle arrest
118-121
. The expression level of the p53 
protein is controlled by MDM2 via ubiquitination and/or inhibition of MDM2 by p14
ARF 
122
. p53 exerts its anti-tumorigenic effects via transcriptional activation of pro-apoptotic 
genes, cell cycle-regulatory genes or DNA-repair genes
118
. The p53 gene is mutated in 
about 50% of all human cancers with a variety depending on the tumor type. In addition, 
several mutations have been associated with tumorigenesis as well as to the tumor treatment 
response
123
. 
As a transcription factor, p53 can regulate both the extrinsic and the intrinsic apoptotic 
pathways. It can induce the expression of death receptors (DR5, DR4 and FAS) as well as 
the expression of pro-apoptotic members of the Bcl-2 family, including Bax, Bid, Noxa and 
Puma
124
. It can also suppress the expression of decoy receptors and anti-apoptotic 
proteins
124
. Upon DNA-damage the activation of p53 occurs via post-translational 
modifications which lead to the regulation of DNA repair pathways in transactivation-
dependent and independent ways. The tumor suppressor is also implicated in mechanism of 
cell cycle arrest which allows for DNA-repair
124
. In situations of excess DNA-damage, p53 
functions switch from pro-survival to pro-apoptotic
124
. A more detailed description of this 
event has, however, not yet been presented. 
Similar to other carcinomas, the p53 gene is mutated in more than 50% of all CRCs 
although with a higher frequency in distal colon tumors
125
. The p53 gene is located on 17q 
and LOH on this chromosome region is, as discussed above, a common trait in CRC. 
Eighty-five percent of these mutations are missense mutations at ‘hotspot’ codons 175, 245, 
248, 249, 273 and 282, which all are located in the DNA binding domain of the protein
126
. 
Studies evaluating the p53 status as a prognostic and a predictive marker are contradictory, 
possibly due to the differences in their methodological approaches
125
. Some studies have 
reported that patients with mutated p53 have an increased risk of death, poor prognosis, as 
well as lower disease free and overall survival
127-129
. In addition, p53 mutations and gene 
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overexpression were associated with shorter survival in patients receiving 5-FU adjuvant 
therapy
129-131
. Remarkably, other studies have not found any supporting evidence that p53 
mutations in CRCs can be used as a prognostic marker
128,132-134
.  
2.3 5-Fluorouracil 
5-Fluorouracil (5-FU) belongs to the fluoropyrimidine type of drugs and is commonly used 
in the treatment of solid tumors. 5-FU was originally generated by Heildelberger et al. in 
1957 based on the finding that rat hepatomas utilized uracil more than normal liver cells. 
Ever since then it has become the mainstay of CRC treatment at high risk stage II, stage III 
and stage IV, either alone or in combination with other drugs
135
. Depending on the dose and 
schedules, it can exert different toxicities such as myelosupression, mucositis and 
diarrhea
136
. For this reason, the third generation of fluorouracil derivatives was introduced 
to lessen the drug toxicity. 
5-FU is a uracil analogue which has a fluorine atom at the C5 position instead of a 
hydrogen atom. It enters the cells via membrane carrier-mediated transport in the same way 
as uracil
137
. The half-life of 5-FU in the plasma is 10 to 20 minutes and approximately 80% 
of 5-FU is catabolized, primarily in the liver, while the rest is excreted in the urine 
unchanged
137
. The first reaction and rate-limiting step in this process is the conversion of 5-
FU to non-active dihydrofluorouracil (DHFU) by dihydropyrimidine dehydrogenase (DPD) 
to reduce the pyrimidine ring which is followed by further enzymatic reactions
138
. 
5-FU is converted to three active metabolites: fluorodeoxyuridine monophosphate 
(FdUMP) fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine triphosphate 
(FUTP). The first two cause DNA damage while the latter exerts its effect on RNA (Fig. 
3)
139
. 
The thymidylate synthase (TS) enzyme converts deoxyuridine monophosphate (dUMP) to 
deoxythymidine monophosphate (dTMP) using reduced folate 5, 10-
methylenetetrahydrofolate (CH2THF) as a cofactor. Irreversible binding of FdUMP to TS 
together with CH2THF results in a stable ternary complex. Inactivation of TS leads to 
imbalance in deoxynucleotide pools and dTTP depletion
140
. As a result, DNA synthesis is 
stopped and consequently stalled replication forks are formed
141
. In addition, FdUTP can 
misincorporate into the DNA directly instead of dTTP. This causes activation of uracil 
glycosylases and subsequently fragmentation of DNA
142
. Incorporation of FUTP into RNA 
can affect RNA processing which in turn leads to formation of immature ribosomal RNAs 
(rRNAs) and misfolded tRNAs
143
. 
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Conversion of 5-FU to fluorouridine monophosphate (FUMP) can either be catalyzed 
directly by orotate phosphoribosyl transferase (OPRT) or indirectly through the sequential 
action of uridine phosphorylase (UP) and uridine kinase (UK) (Fig. 3). If phosphorylation 
of FUMP to fluorouridine diphosphate (FUDP) is followed by another phosphorylation it 
forms fluorouridine triphosphate (FUTP)
139
. Alternatively, it can be converted to 
fluorodeoxyuridine diphosphate (FdUDP) by ribonucleotide reductase (RR). Further 
phosphorylation or dephosphorylation leads to the formation of FdUTP and FdUMP, 
respectively. An alternate pathway catalyzes the conversion of 5-FU to fluorodeoxyuridine 
(FUDR) which is then phosphorylated to FdUMP by the enzymatic actions of thymidine 
phosphorylase (TP) and thymidine kinase (TK)
139
. 
 
FIGURE 3. 5-FU metabolism. 
Reprinted with permission from Macmillan Publishers Ltd: [Nature Reviews Cancer] (Longley DB, Harkin 
DP, Johnson PG)
139
, copyright (2003) http://www.nature.com/nrc/journal/v3/n5/abs/nrc1074.html 
Treatment strategies of CRCs differ according to the stage of the disease. For stages I-II the 
predominant approach is surgical resection, for high-risk stage II or stage III - adjuvant 
chemotherapy, and for stage IV is chemotherapy. The response rate to 5-FU alone as an 
adjuvant chemotherapy is 10-15%
144
. However, combinatory treatment with oxaliplatin and 
irinotecan increases the response rates to 40-50% with a better overall survival
145,146
. The 
catalyzing efficiency and alterations of enzymes responsible for 5-FU metabolism have 
been investigated deeply in order to identify predictive and prognostic markers. Studies 
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showed that low TS expression was associated with an improved response rate to 5-FU and 
acute increase in TS enzyme levels can be responsible for drug resistance
147-150
. High levels 
of DPD and dUTPase correlated with resistance to TS inhibitors 
151,152
. Moreover, increased 
levels of TP, UP, UK and OPRT are also coupled with 5-FU sensitivity
153-155
. It should be 
noted that primary tumors and metastases may differ in their sensitivity to chemotherapy. 
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3. AIM OF THE STUDY 
The main aim of this thesis was to investigate in detail still poorly characterized stress 
signaling pathways elicited by 5-FU metabolites. 
The specific aims were as follows: 
1. To characterize the DISC formation induced by 5-FU in order to investigate initial 
apoptotic triggering points and define potential upstream regulatory factors of the 
caspase cascade. 
2. To study the involvement of the p53 protein and its phosphorylations in 5-FU-
mediated cell death and identify upstream regulators of p53 phospho-activations 
including calcium (Ca
2+
) signaling. 
3. To examine reciprocal or unilateral cross-talk between autophagy and apoptosis 
with respect to 5-FU generated stress. 
4. To analyze the mechanism of DR activation in tumor cells treated with 5-FU. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  23 
4. MATERIALS AND METHODS 
A detailed description of the materials and methods used in this thesis can be found in 
papers I-III. The section below provides a brief summary. 
4.1 Cell culture 
The cell lines used in Papers I-III are summarized in Table 1. 
Table 1. Cell lines employed in the study. 
Cell line Growth medium Paper I Paper II Paper III Source 
HCT116 wt DMEM    a 
HCT116 wt c-FLIPL overexpressing DMEM    a-c 
HCT116 wt BclXL overexpressing DMEM    a-c 
HCT116 wt FADD-DN  DMEM    a-c 
HCT116 Chk2
-/-
 DMEM    b 
HCT116 p53
-/-
 DMEM    b 
HCT116 p53
-/-
 c-FLIPL overexpressing DMEM    b-c 
HCT116 p53
-/-
 FADD-DN DMEM    b-c 
A549 RPMI-1640    a 
RKO DMEM    a 
HT-29 DMEM    a 
a Cell lines purchased from American Type Culture Collection (ATCC, Manassas VA). 
b Cell lines provided by Professor Bert Vogelstein (Department of Oncology, John Hopkins University,USA). 
c Phoenix-Ampho packaging cell line was provided by Dr. Garry Nolan, Stanford University, USA). 
Growth mediums (DMEM, RPMI-1640, GIBCO) were supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (v/v) (GIBCO) and PenStrep (100 U/mL penicillin, 
100 µg/mL streptomycin, Sigma-Aldrich). Throughout the experiments cells were 
maintained in a logarithmic growth phase at 37ºC in an atmosphere containing 95% 
humidity and 5% CO2. All experiments were performed using cell lines between passages 4 
and 20. Cells were seeded at a density of 40,000-50,000 cells/cm
2
 and then allowed to 
adhere for 24 h before being exposed to treatments. For each experiment, the treatment 
conditions and incubation times are indicated in the corresponding figures. 
4.2 Drugs and chemicals 
The drugs, chemical inhibitors, antioxidants and metabolites used in Papers I-III are 
summarized in Table 2. All inhibitors were added to cell cultures at least 1 h prior to drug 
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treatment, unless otherwise stated. Further details regarding the use of drugs and chemicals 
can be found in the papers included in the thesis. 
Table 2. The drugs and chemical inhibitors employed in the study. 
Name Source Final concentration 
Drugs 
5-Fluorouracil (5-FU) Teva-Accord 10-768 µM 
Camptothecin Sigma-Aldrich 600 nM 
Cisplatin Ebewe 40 µM 
Doxorubicin Sigma-Aldrich 2 µM 
Etoposide Ebewe 20 µM 
Leucovorin (Leu) Hospira 4.9-78.2 µM 
Metabolites 
Uridine Sigma-Aldrich 375 µM 
Thymidine Sigma-Aldrich 375 µM 
Recombinant Proteins 
Recombinant TRAIL Thermo Fisher Sci. 10-100 ng/mL 
Recombinant soluble DR5 Sigma-Aldrich 2 µg/mL 
Inhibitors 
BAPTA Invitrogen 10 µM 
Thapsigargin Invitrogen 1-5 µM 
Verapamil Sigma-Aldrich 10-60 µM 
N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) 
fluoromethyl ketone (zVAD-fmk) 
Peptide 10 µM 
Olaparib Selleck Chemicals 500 nM 
E64d Sigma-Aldrich 10 µM 
Pepstatin A Sigma-Aldrich 7-10 µM 
Leupeptin Sigma-Aldrich 100 µM 
CA-074 methyl ester Merck  10 µM 
Calmidazolium chloride Santa Cruz 2.5-5 µM 
Fluphenazine-N-2-chloroethane Santa Cruz 2.5-10 µM 
PKC412 Novartis 0.001-5 µM 
KU55933 Selleck Chemicals 7.5-10 µM 
SB203580 Selleck Chemicals 10 µM 
Brefeldin A (BFA) Sigma-Aldrich 2-1000 nM 
Chloroquine (CQ) Sigma-Aldrich 10-100 µM 
Bafilomycin A (Baf A) Sigma-Aldrich 100 nM 
3-methyladenine (3-MA) Sigma-Aldrich 5 mM 
U18666A Sigma-Aldrich 0.1-5 µg/mL 
Methyl-β-cyclodextrin (MβCD) Sigma-Aldrich 2.5-5 mM 
PUGNAc Sigma-Aldrich 25-100 µM 
Benzyl-α-galNAc Sigma-Aldrich 2.5 mM 
Necrostatin-1 (Nec-1) Merck 100 µM 
Necrostatin-1, inactive control Merck 100 µM 
Antioxidants   
Trolox Merck 50 µM 
N-acetylcysteine (NAC) Merck 5 mM 
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4.3 Gel electrophoresis and immunoblotting 
Floating and attached cells were harvested by trypsinization, centrifuged at 1300 rpm for 5 
min, washed in phosphate-buffered saline (PBS) and then centrifuged at 2000 rpm for 10 
min. The cell pellet was subsequently lysed for 10 min at room temperature (RT) in 
cOmplete Lysis-M containing cOmplete protease and phosphatase inhibitor cocktails 
(Roche Diagnostics). The BCA Protein assay (Thermo Fisher Scientific) was used to 
determine protein concentration. Samples were mixed with 5X Laemmli sample buffer and 
after denaturation for 10 min at 95ºC, 20-80 µg of each sample was subjected to sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS–PAGE) in cold Tris-glycine-
SDS running buffer at 80-120 V and electroblotted to 0.45 µM nitrocellulose membranes 
(Bio-Rad Laboratories) using Tris-glycine transfer buffer containing 20% methanol (v/v) 
for 2 h at 90 V in a wet blotting system (Bio-Rad Laboratories). Membranes were then 
blocked with 5% non-fat milk in Tris-buffered saline with Tween-20 (TBST) for 1.5 h at 
RT and probed with the primary antibody of interest diluted in PBS containing 1% BSA, 
0.05% Tween-20 and 0.01% NaN3 at 4ºC overnight (Table 3). Membranes were washed 3 
times in TBST for 5 min and 3 times in TBS for 10 min each and then incubated with 
horseradishperoxidase-conjugated secondary antibodies, which were diluted in blocking 
solution for 2 h at RT. After washing, all steps were repeated. Finally, signals were revealed 
by ECL (GE Healthcare Biosciences) and membranes were exposed to SuperRX-N X-ray 
films (Fujifilm Corporation). 
4.4 Isolation of membrane proteins 
Cytosolic and membrane fractions were isolated using the Qproteome Cell Compartment 
Kit (Qiagen) in accordance with the manufacturer’s instructions and, following 
denaturation, subjected to SDS-PAGE. 
4.5 DR5 dimerization 
To investigate DR5 dimers cells were treated as indicated in the related paper. After lysing 
for 20 min on ice in non-reducing Triton buffer (20 mM Tris base, pH 7.5, 150 mM NaCl, 
10% glycerol, 1% Triton-X100 and 1 mM EDTA) containing cOmplete phosphatase and 
protease inhibitors, cells were treated with benzonase nuclease (Sigma-Aldrich) for 15 min 
at RT. After centrifugation at 16,000 g at 4ºC samples were mixed with 3X Laemmli 
sample buffer with or without β-mercaptoethanol. The samples containing reducing agent 
were denatured at 95ºC for 10 min while the non-reduced samples kept at RT before 
subjected to SDS-PAGE, as described above. 
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Table 3. Antibodies used in western blotting (WB), immunofluorescence 
(IF),immunoprecipitation (IP) and flow cytometry (FCM). 
Name Source Method-Dilution 
p53 (DO-1), mAb Santa Cruz WB 1:5000, IF 1:400 
phospho-p53 (Ser 6,9,15,33,37,46,382), pAb Cell Signaling WB 1:1000 
DR5, pAb Sigma-Aldrich WB 1:5000 
DR5 (F2/B4), mAb a IF 1:100, IP 1:, FCM 1:100 
DR4, pAb Sigma-Aldrich WB 1:1000 
DR4, mAb a IF 1:100, FCM 1:100 
FAS pAb Santa Cruz WB 1:1000, IF 1:100 
Transferrin (MEM-75), mAb Abcam IF 1:100, FCM 1:100 
FADD, pAb Upstate Biotechnologies WB 1:1000, IF 1:100 
TRAIL, mAb BD Biosciences WB 1:1000 
cFLIP b WB 1:10 
caspase-8 (C15), mAb b WB 1:50 
caspase-7 (B94-1), mAb BD Biosciences WB 1:1000 
cleaved-caspase-3, pAb Cell Signaling WB 1:1000 
caspase-2 clone 35, mAb BD Biosciences WB 1:5000 
Bcl-xL, pAb Santa Cruz WB 1:1000 
PARP (4C10-5), mAb BD Biosciences WB 1:1000 
cleaved PARP (Asp214), mAb  Cell Signaling WB 1:1000 
cleaved lamin A, mAb Cell Signaling WB 1:1000, IF 1:200 
ATF-3 pAb Santa Cruz WB 1:1000 
anti-PAR mAb Trevigen WB 1:1000 
ATM (D2E2), mAb  Cell Signaling WB 1:1000 
γH2AX (Ser139), pAb Cell Signaling WB 1:1000 
PERK, Cell signaling WB 1:3000 
SQSTM1 (p62) mAb Santa Cruz WB 1:2000 
Atg5, pAb Cell Signaling WB 1:1000 
Atg7, pAb Cell Signaling WB 1:1000 
beclin, pAb Cell Signaling WB 1:1000 
LC3, pAb  MBL WB 1:5000, IF 1:100 
anti-AIF (E-1), mAb Santa Cruz WB 1:1000 
cytochrome c BD Biosciences WB 1:2000, IF 1:400 
Tom-40 pAb Santa Cruz WB 1:10000 
GAPDH pb Trevigen WB 1:5000 
tubulin (B-5-1-2), mAb Sigma-Aldrich WB 1:10000 
Ku80, mAb BD Biosciences WB 1:10000 
Secondary antibodies    
Anti mouse, rabbit, goat Thermo Fischer WB 1:5000-10000 
Alexa 488 anti-mouse, rabbit, goat Molecular Probes IF 1:200, FCM 1:200 
Alexa 594 anti-mouse, rabbit, goat Molecular Probes IF 1:200, FCM 1:200 
a Provided by Dr. L Andêra, Academy of Sciences, Prague, Czech Republic 
b Provided by Prof. PH Krammer and Dr. I Lavrik, German Cancer Research Center, Heidelberg, Germany 
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4.6 Release of mitochondrial AIF and cytochrome c 
To detect the release of mitochondrial AIF and cytochrome c, cells were treated, harvested 
by trypsinization, centrifuged at 1300 rpm for 5 min and washed in PBS. Subsequently, 
cells were permeabilized with digitonin (0.01% w/v) in fractionation buffer (150 mM KCl, 
10 mM Tris, 1 mM MgCl2) for 15 min at RT, centrifuged at 13,000 g to separate the 
cytosol from pelleted nuclear/mitochondrial/membrane proteins. After determination of 
protein concentration by the BCA protein assay, samples were subjected to SDS-PAGE as 
described above. 
4.7 Analysis of the mitochondrial membrane potential and reactive 
oxygen species (ROS) 
Cells were incubated for 20 min in Hank’s balanced salt solution (Life Technologies) 
containing 0.1 µM tetra-methyl-rhodamine-ethyl ester (TMRE, Life Technologies). Loss of 
mitochondrial membrane potential (ΔΨm) in live cells was then examined by flow 
cytometric analysis of mitochondrial accumulation of TMRE. 
For assessment of mitochondrial ROS, cells were stained with MitoSOX™ Red (Life 
Technologies) in accordance with the manufacturer’s instructions. Analyses were 
performed with a FACScan Becton Dickinson flow cytometer and the accompanying 
software.  
4.8 Expression vectors and retroviral transduction 
Retroviral particles were produced by transient transfection of the Phoenix-Ampho 
packaging cell line (kindly provided by Dr. GP Nolan, Stanford University, USA) using the 
retroviral expression vectors pLXIN-hBcl-XL, pLXIN-hFADD and pXIN-hFLIPL which 
have been described previously
156
. Transduced cells were selected by treatment with 
Geneticin (1 mg/mL, Invitrogen) for one week. 
4.9 Vectors and cloning 
Wild type (wt) p53 and p53 (S15A) cDNA’s were kindly provided by Prof. Moshe Oren 
(Weizmann Institute of Science, Rehovot, Israel). Subsequent to deletion of the stop codons 
to allow GFP expression, wt and mutated p53 sequences were subcloned into the Xba1-
BamH1 site of the pCDH-CMV-MCS-EF1-copGFP expression vector (System 
Biosciences). Lentiviral packaging was accomplished using the LentiSuite™ in accordance 
with the manufacturer´s instructions (System Biosciences). Then, transductions of HCT116 
p53
-/-
 cells were performed by incubation under normal culturing conditions in the presence 
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of virus for 24 h. Transfected cells were then sorted using the FACSVantage/DiVa system 
(Becton Dickinson) together with the accompanying software. 
4.10 RNA isolation and RT-PCR 
Total RNA was isolated with the RNAeasy mini kit (Qiagen) in accordance with the 
manufacturer’s instructions. The Maxima First Strand cDNA Synthesis Kit (Thermo 
Scientific) or Transcriptor First Strand cDNA Synthesis Kit (Roche) were used for cDNA 
synthesis. Gene expression was measured using the Maxima SYBR Green qPCR Master 
Mix (Thermo Scientific) or the FastStart SYBR Green Master (Roche) together with the 
Applied Biosystems 7500 Real-time PCR technology (Applied Biosystems). 50 ng cDNA 
and 300 nmol primers were used (Table 4) in each reaction. Relative gene expression was 
calculated by the 2
-ΔΔ
Ct procedure using expression of actin and GAPDH for 
normalization. 
Table 4. Primers employed in the study. 
Primers Forward sequence Reverse sequence 
DR5 TCAGGTGAAGTGGAGCTAAGTC GTGTACAATCACCGACCTT 
DR4 ACTCGCTGTCCACTTTCGTCTCTGA AGGCATCCCCTGGGCCTGCTGTA 
Actin GCTGTGCTATCCCTGTACGC GAGGGCATACCCCTCGTAGA 
GAPDH CCTGGCCAAGGTCATCCATG TGAGGTCCACCCTGTTG 
4.11 RNA interference 
Silencing of protein expression in cells was performed using the Lipofectamine RNAiMAX 
(Life Technologies) or INTERFERin transfection reagent (Polyplus transfection) in 
accordance with the manufacturer’s instructions.  
In brief, when reaching 60-80% confluence, cells were transfected in complete cell culture 
medium without PenStrep using 10-20 nM final concentration of siRNA and 3.5 µl/mL 
transfection reagent (Table 5). Depending on the experiment, target protein suppression 24-
72  h post-transfection was confirmed by SDS–PAGE as described above. 
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Table 5. The siRNAs employed in the study. 
Name Source 
Human TNFSF10, Silencer Select Thermo Fischer Scientific 
Hs-TNFSF10-6, FlexiTube Qiagen 
Hs-TNFSF10-7, FlexiTube Qiagen 
Human TNFRSF10A (8797), ON-TARGET plus, SMARTpool Dharmacon 
Human TNFRSF10A, Silencer Select Thermo Fischer Scientific 
Human TNFRSF10B (8795), ON-TARGET plus, SMARTpool Dharmacon 
Human TNFRSF10B, Silencer Select Thermo Fischer Scientific 
siDR5(h) Santa Cruz 
Human FAS (355), ON-TARGET plus, SMARTpool Dharmacon 
Human CASP8 (841), ON-TARGET plus, SMARTpool Dharmacon 
Hs-TP53-9, FlexiTube Qiagen, 
Hs-ATM-8, FlexiTube Qiagen, 
Hs-ATM-9, FlexiTube Qiagen, 
Hs-ATM-12, FlexiTube Qiagen, 
siPARP1, HP Custom siRNA Qiagen, 
Human BCN1, ON-TARGET plus, SMARTpool Dharmacon 
SQSTM1, Silencer Select Thermo Fischer Scientific 
Human ATG5, ON-TARGET plus, SMARTpool Dharmacon 
Human ATG7, ON-TARGET plus, SMARTpool Dharmacon 
Negative Control No. 1, Silencer Select Thermo Fischer Scientific 
Human Non-Targeting Pool 1, siGENOME Dharmacon 
4.12 Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) was used to determine changes in the 
morphology of detached (paper II) and attached (paper III) cells in response to treatment. 
Cells were trypsinized, spun down, resuspended in fixing solution (2.5% w/v, 
glutaraldehyde in 0.1 M phosphate buffer, pH 7.4) for 30 min at RT. After washing in 0.1 
M phosphate buffer, cells were centrifuged, pellets post fixed in 2% (w/v) osmium tetroxide 
in 0.1 M phosphate buffer (pH 7.4) for 2 h at 4ºC, dehydrated in ethanol followed by 
acetone, and embedded in LX-112 (Ladd). Serial ultrathin sections (∼40–50 nm) were cut 
using a Leica EM UC 6 ultramicrotome. The contrast of the sections was subsequently 
enhanced with uranyl acetate followed by lead citrate and examined in a Tecnai 12 Spirit 
Bio TWIN transmission electron microscope (FEI) at 100 kV. Digital images were recorded 
using a Veleta camera (Olympus Soft Imaging Solutions). 
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4.13 Immunofluorescence 
Cells were seeded onto coverslips and treated as indicated in the papers. After fixation for 
10 min at 4ºC in 4% formaldehyde, the cells were washed in PBS. For proteins other than 
transmembrane proteins, cells were permeabilized in PBS containing 0.1% Triton X-100 
for 10 min at RT, blocked with 1% BSA in PBS for 1 h at RT and incubated with the 
primary antibodies of interest (previously blocked with 1% BSA for 2 h at RT) at 4ºC 
overnight in a humidity chamber (Table 3). After washing the samples, secondary 
antibodies diluted in 1% BSA were added for 2 h at RT and protected from light. Nuclei 
were counterstained with Hoechst 33342 (10 μg/mL in PBS). Between all steps, the cells 
were washed 3 times in PBS for 5 min each. Finally, the coverslips were mounted using 
Vectashield H-1000 (Vector Laboratories) or Prolong Gold antifade reagent with DAPI 
(Life Technologies). 
Plasma membrane co-staining was achieved by incubating fixed cells in the presence of 
FITC-conjugated cholera toxin B (CTB; 0.2 μg/mL; Sigma-Aldrich) for 15 min at RT in the 
dark. Similarly, free cholesterol was detected by Filipin III (50 μg/mL, Sigma Aldrich) in 
PBS supplemented with 10% FBS and incubation for 2 h at RT in the dark. 
Lysosomes were visualized with LysoTracker® Red DND-99 (Molecular probes
TM
) in 
accordance with the manufacturer´s instructions. In brief, 100 nM of this dye was added to 
the media of control or treated cells for 30 min in advance of washing and fixing 
procedures. All samples were examined under a Zeiss LSM 510 META confocal laser 
scanner microscope (Carl Zeiss). 
4.14 Measurement of caspase-3/-7-like activities 
After washing, cells were suspended in PBS and mixed with peptide substrate diluted in 
100 mM HEPES, 10% sucrose, 5 mM DTT, 0.001% NP-40 and 0.1% CHAPS, pH 7.3. 
Cleavage of the caspase-3/-7-like substrate Ac-DEVD-AMC (acetyl Asp-Glu-Val-Asp 7-
amido-4-methylcoumarin, Peptide Institute) was monitored in a Fluoroscan II plate reader 
(Labsystems) at excitation and emission wavelengths of 355 nm and 460 nm, respectively. 
4.15 Colony assay 
Eighteen cells per cm
2 
were seeded in 100 mm cell culture dishes one day in advance of 
experiments and then treated for 48 h. Drug-containing media were then replaced with 
normal media and cell colonies were allowed to form over 10 days before fixation in 100% 
methanol on ice for 10 min and staining in 0.04% (w/v) crystal violet solution. 
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4.16 Calcium measurements 
Intracellular calcium levels were monitored using the Fluo-4 AM fluorescent indicator 
(Invitrogen). In brief, 4 μM of the calcium probe was added to cells 30 min in advance of 
treatments. Time-lapse analysis of living cells was then performed using the Zeiss LSM 
510 META confocal laser scanner microscope or the FACS Calibur system in combination 
with the CellQuest v.3.3 software (Becton-Dickinson). 
4.17 Measurement of lactate dehydrogenase (LDH) release 
The amount of lactate dehydrogenase (LDH) released, a marker for plasma membrane 
integrity, or necrosis, was determined using the fluorometric Cyto Tox-ONE Homogeneous 
Membrane Integrity Assay (Promega) in accordance with the manufacturer’s instructions. 
4.18 Sub-G1 analysis 
Cells were harvested and fixed in 70% ethanol for 1 h at 4ºC. Repeated washes in cold PBS 
and RNase A treatment (100 µg/mL, Invitrogen) for 1 h at 37ºC were followed by 
propidium iodide staining (40 µg/mL, Sigma-Aldrich). Analysis in the FL3 channel in 
DDM mode was performed using the BD Accuri C6 system in combination with the BD 
CSampler software (Becton-Dickinson). 
4.19 Quantification of plasma membrane receptors 
The level of plasma membrane receptors was detected in cells after incubation with specific 
antibodies using flow cytometry analysis of live cells. Cells were treated, harvested by 
trypsinization, centrifuged at 1300 rpm for 5 min, washed in ice cold PBS supplemented 
with 5% FBS and centrifuged at 2000 rpm for 10 min. Cells were incubated with primary 
antibodies (anti-DR4, -DR5, and -transferrin) diluted 1:100 in washing solution (Table 3). 
Cells were then washed twice, and incubated at 4ºC for 30 min with the secondary antibody 
(AlexaFluor-488-conjugated donkey anti-mouse-IgG). After washing twice, the cells were 
stained at 4ºC for 15 min with 7-AAD (1 μg/mL, Molecular ProbesTM), which allowed for 
the gating of living cells, and analyzed by flow cytometry (FACScan, Becton Dickinson). 
The 7-AAD-negative cells were subjected to receptor analysis (Cell Quest software). Green 
fluorescence indicating the amount of the receptor present at the plasma membrane versus 
cell counts are visualized in histograms, enabling comparisons of control and treated cell 
populations, and related to control cell samples lacking the specific primary antibody. 
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4.20 Immunoprecipitation of DR5 
Cells were lysed on ice for 15 min in NP-40 lysis buffer (50 mM Tris, pH 8.0, 150 mM 
NaCl, 1% NP-40) supplemented with PMSF 0.1 µg/mL, cOmplete protease and 
phosphatase inhibitor cocktails (Roche). After sonication and centrifugation 1 mg of the 
protein extract was incubated with 2 µg DR5 mAb (clone F2/B4) at 4ºC overnight. Proteins 
were then bound to Protein-G Sepharose 4 Fast Flow (GE Healthcare) and the beads 
washed 3 times in lysis buffer for 5 min each, diluted 1:1 in reducing 2xLaemmli buffer, 
and subjected to SDS-PAGE after denaturation. 
4.21 Statistical analysis 
The results are expressed as means ± standard deviations (SD). The GraphPad Prism 5.02 
software and the t-test were used for analysis. 
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5. SUMMARY OF THE PAPERS 
Paper I: 
Can G
1
, Akpinar B
1
, Baran Y, Zhivotovsky B, Olsson M 
(
1
 denotes equal contribution). 
5-Fluorouracil signaling through a calcium–calmodulin-dependent pathway is required for 
p53 activation and apoptosis in colon carcinoma cells. 
Oncogene 2013 Sep 19; 32(38): 4529-38. 
5-Fluorouracil (5-FU), a uracil analogue, is used to treat various solid cancers, including 
colon carcinoma. Active metabolites of this compound develop their effects via DNA 
damage and RNA stress, but the relative importance of each triggering points remains 
elusive. 
In Paper I we investigated the effects of 5-FU-induced cell death in the colon carcinoma 
cell line HCT116 in more detail, especially with respect to initial targets and ensuing death 
signaling. Upon 5-FU treatment, not only DR5 but also the FAS receptor accumulated in 
the plasma membranes. However, only DR5 is required for effective formation of the 
death-inducing signaling complex (DISC) and initiation of apoptosis as confirmed by 
siRNA silencing, immunostaining and fractionation of the membranes of control and 
treated cells. In addition, the process is facilitated by p53. 
To identify initial factors important for stabilization of p53 and formation of the DISC, the 
Ca
2+
-chelator BAPTA, the RIP1-kinase inhibitor NEC1, the antioxidant Trolox, the acid 
protease inhibitor pepstatin A or the cathepsin B inhibitor CA-072 were used in 
combination with 5-FU. We found that lysosomal proteases promote effector caspase 
activity downstream of the DISC formation, while Ca
2+
-dependent calmodulin-mediated 
phosphorylation of at least three p53 serine phosphorylation sites (S15, S33, S37) act 
upstream of caspase activation. 
Since the level of phospho-p53 activation at the serine 15 (S15) site was significantly 
decreased in the presence of BAPTA, we reintroduced wt and p53 mutated at the S15 
phospho-site into HCT116 p53
-/- 
cells using lentiviral transfection technology and found 
that the S15 phosphorylation is necessary for activation of caspase-8 and cleavage of 
PARP. Indeed, intracellular levels of Ca
2+ 
rose during the early hours of 5-FU treatment and 
remained for as long as 13 h. Ca
2+ 
was found to enter the cells at least partially via L-type 
channels and Ca
2+ 
originating from the endoplasmic reticulum contributed neither to the 
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phospho-p53 status nor the cell death. In line with these observations, HCT116 cells 
harboring a mutant S15 p53 showed a 50% reduction in their apoptotic response to 5-FU. 
Altogether, the obtained results present the evidence of a novel apoptotic mechanism 
induced by 5-FU, dependent on extracellular Ca
2+
, involving DR-DISC and regulated by 
p53, p53 phosphorylation and calmodulin. 
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Paper II: 
Akpinar B, Bracht EV, Reijnders D, Safarikova B, Jelinkova I, Grandien A, Vaculova AH, 
Zhivotovsky B, Olsson M. 
5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis 
facilitated by p53. 
Oncotarget 2015 Dec 22; 6(41): 43679-43697. 
Although 5-fluorouracil (5-FU) was discovered more than 50 years ago it is still commonly 
used for the treatment of several solid tumors. Primary drug effects relate to both DNA and 
RNA damage. The tumor suppressor protein p53 is mutated or not functional in most 
human cancers. Therefore, in Paper II we focused on cell death signaling pathways in 5-
FU-stressed p53
-/-
 cells. 
Using the human colon carcinoma parental cell line HCT116 and its variant lacking p53, 
we found that the cell death per se induced by 5-FU is independent of p53. However, in the 
absence of the tumor suppressor, the appearance of all apoptotic markers examined, 
including loss of the mitochondrial membrane potential (MMP, ΔΨm), release of 
cytochrome c into the cytosol, DEVDase (caspase-3/-7-like) activity and poly (ADP-ribose) 
polymerase-1 (PARP-1) cleavage was delayed. 
Notably, in contrast to its wt counterpart, the HCT116 p53
-/-
 cell line exposed to 5-FU 
exhibited a necrotic morphology and prominent release of lactate dehydrogenase (LDH). 
However, since these necrotic features were eliminated by a pan-caspase inhibitor (zVAD-
fmk), they were concluded to be caspase-dependent. In addition, suboptimal apoptotic 
conditions due to lack of p53 were associated with the formation of ROS in mitochondria. 
Similar to the parental cell line, 5-FU treatment of p53-deficient cells led to formation of 
DISC in a TRAIL-dependent manner. Co-treatment with zVAD-fmk and 5-FU revealed 
that DNA damage reflected in phosphorylation of the histone H2AX (γH2AX) is a 
consequence of apoptosis. Finally, our data suggest that silencing of PARP-1 function can 
sensitize the p53-deficient cells to 5-FU. 
In conclusion, the data presented here enhance our understanding of factors that limit the 
efficacy of 5-FU. By excluding DNA as the main stress target in at least certain types of 
cells, our observations suggest alternatives to currently used synergistic treatment regimens. 
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Paper III: 
Akpinar B, Safarikova B, Lauková J, Debnath S, Vaculova AH, Zhivotovsky B, Olsson M. 
Aberrant DR5 transport through disruption of lysosomal function suggests a novel 
mechanism for receptor activation. 
Manuscript, re-submitted after revision.  
Autophagy and apoptosis determine the turnover of cytosolic organelles and intact cells, 
respectively. In Paper III, reciprocal and/or unilateral interactions between these processes 
were examined in 5-FU-treated tumor cells employing a combination of chemical 
inhibitors, RNAi and genetic approaches. In contrast to cells with blocked apoptosis, either 
at the DISC or the mitochondrial level, p53 deficiency was associated with signs of 
deregulation of autophagy in response to 5-FU, including failure to induce degradation of 
p62 and elevated expression of LC3. Of the strategies utilized to prevent autophagy, 
disruption of lysosomal function with chloroquine (CQ) caused a profound reduction in the 
levels of apoptotic markers in 5-FU treated cells, with DR5, a death receptor member of the 
TNF-family essential for 5-FU-induced apoptosis, accumulating in lysosomes and 
autophagosomes upon treatment. 
Since 3-MA, RNAi targeting of critical regulators of autophagy or inhibition of lysosomal 
cathepsins reversed apoptosis in different manners, it is unlikely that autophagy per se, but 
rather correct receptor transport is an important factor for 5-FU-induced cell death. 
Interestingly, apoptosis activated via TRAIL, the cognate ligand for DR5, remained 
unaffected in the presence of CQ, indicating that 5-FU activates the receptor by a discrete 
mechanism. A distinction between ligand- and chemotherapy-induced apoptosis could also 
be confirmed by introducing malfunction of protein transport from the ER to the Golgi with 
brefeldin A. Through depletion of membrane cholesterol or inhibition of cholesterol 
transport with methyl-β-cyclodextrin or U18666A, respectively, the cytotoxicity of 5-FU 
was drastically reduced. Moreover, as with CQ, treatment with U18666A alone or in 
combination with 5-FU led to the accumulation of DR5 in the cytosol, thereby supporting 
the idea that correct trafficking of the receptor is important for 5-FU-mediated elimination 
of cells. 
In conclusion, this study indicates a novel chemotherapy-induced mechanism for activation 
of DR5, which may have important ramifications on research conducted in the fields of 
apoptosis and tumor treatment. 
 
  37 
6. DISCUSSION 
DR5, one of the TRAIL receptors, has a prospective therapeutic application in cancer 
therapy since it was reported that TRAIL has the ability to kill cancer cells selectively
157
. 
Therefore, a better understanding of DR5 signaling pathways can help to develop new 
targeted therapeutic approaches. Analysis of tumor samples revealed that expression of 
DR5 is downregulated progressively with increased stage in CRC and mutations in DRs 
have been associated with tumor progression
158-162
. 5-FU can trigger the extrinsic apoptotic 
pathway, however detailed information related to how the signaling reaches to the DRs is 
still missing. 
In the present study we investigated the 5-FU-mediated cell death signaling in HCT116 
cells. 
We have shown that upon 5-FU treatment, both FAS and DR5 localized to the plasma 
membrane but only the latter promoted caspase processing. In paper I, we concluded that a 
significant increase in intracellular calcium levels particularly through the L-type voltage-
dependent calcium channels is an early response to 5-FU. 
Stabilization and function of p53 is regulated not only by MDM2 but also by 
posttranslational modifications including phosphorylations. In humans, p53 can be 
phosphorylated on several serine and threonine residues upon DNA damage, ionizing 
radiation and endoplasmic reticulum stress leading to different molecular outcomes
163
. In 
support of our observations, alterations in the intracellular Ca
2+
 level have previously been 
linked to the regulation of apoptosis and p53 phosphorylations
164
. 
We confirmed that p53 is stabilized in a time-dependent manner and also phosphorylated 
on several sites (ser15, 33, 37, 46, 6, 9, 392) upon 5-FU treatment as another early 
response. Therefore, we speculated that the Ca
2+
 response may be associated with p53 
phosphorylations. There are several kinases that may promote p53 phospho-activation but 
due to the increase in intracellular Ca
2+ 
levels we focused on those that are Ca
2+
-related. 
Indeed, inhibition of Ca
2+
 by the chemical inhibitor BAPTA revealed that at least three 
serine residues (ser15, 33, 37) were affected. Out of three, only ser15, upstream of DISC 
formation, had an important role in caspase-8 and -3 activities and PARP cleavage. It 
should also be noted that mutation of the ser15 position did not affect DR-5 dimerization 
indicating that 5-FU-induced DISC formation is indeed p53-independent.  
In agreement with our data, it has been reported that the ser15 phosphorylation site is 
important for efficient p53 stabilization and apoptosis
165-167
. Inhibition of ATM and 
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p38MAP kinase using chemical inhibitor or siRNA did not alter ser15 phosphorylation. 
Although this is in contrast with previous studies, suggesting that ATM, Chk2 and 
p38MAP kinases phosphorylate ser15, it is in support of the fact that alternative routes do 
exist
168-170
. Despite the discrepancy, we do not ignore that these factors can be important in 
5-FU-mediated cell death by other mechanisms. Moreover, 5-FU-treatment of Chk2-
deficient cells caused slower processing of caspase-8 and -3 compared to the parental cell 
line without affecting ser15 phosphorylation, demonstrating that this kinase may have a role 
in 5-FU induced apoptosis separated from p53. 
Ligation of TRAIL to its cognate receptors DR4 and DR5 leads to DISC formation and 
apoptosis
157
. Thus, we subsequently tested whether 5-FU-induced DISC formation involves 
TRAIL. A soluble recombinant DR5 lacking the intracellular domain did not alter the 
apoptotic response to 5-FU whereas downregulation of the TRAIL protein by siRNA in the 
same treatment condition abrogated caspase-3 and PARP cleavage, indicating that 5-FU 
mediated apoptosis depends on intracellular TRAIL. Interestingly, ER stress-induced ligand 
independent DR5 activation has also been described
172
. In addition, co-treatment with 
recombinant TRAIL and 5-FU sensitized the HCT116 cells to apoptosis (Fig. 4A). Similar 
to our findings, Ganten et al. reported that 5-FU-induced DISC formation increased the 
apoptotic response to TRAIL by means of cFLIP downregulation
 171
.  
There are conflicting data regarding p53 status and the tumor response to chemotherapy. 
Studies in breast and colon cancer cell lines and xenograft tumors revealed that loss of p53 
reduced chemosensitivity to 5-FU
130,150,173
. In addition, p53 point-mutations and 
overexpression in CRC patients at stage III and IV were associated with poor prognosis and 
resistance to chemotherapy
130,131,174
. On the other hand, Paradiso et al. could not find any 
correlation between p53 status and 5-FU sensitivity
175
. However, it should be noted that in 
40-50% of all p53 overexpression incidents there is no correlation with mutations of the 
corresponding gene. In consideration of reported data, it seems that p53 can affect the 
response in a disease stage-dependent manner. 
In paper II, we performed an evaluation of sensitivity to 5-FU with respect to p53 cell 
status, which, given that the tumor suppressors can be activated both upon DNA and RNA 
damage, is of particular importance 
176
. In the absence of p53, DR4 and DR5 were still 
upregulated both at the protein and the mRNA levels, although to a lesser extent since they 
are p53 targeted genes. For this reason, the DR5-DISC was still formed in a slow manner. 
Downregulation of caspase-8, DR5, DR4 or TRAIL abrogated cell death independently 
from the p53 status. A 5-FU-induced cell cycle arrest in G1-S phase and all apoptotic 
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markers that were identified in p53 wt cells were also present in p53
-/-
 cells but less 
pronounced and at later time points, indicating that absence of p53 does not change the cell 
death mode. Altogether, 5-FU-induced formation of the DISC should not be considered as a 
p53-dependent, but rather a p53-facilitated event. 
Involvement of ROS in apoptosis and its relation to p53 were analyzed in several studies in 
order to cope with drug resistance
177-180
. HCT116 cells are type II cells which require 
involvement of mitochondria during apoptosis. We confirmed that absence of p53 caused 
an inefficient apoptosis coupled with ROS formation. Based on the TEM images, we 
observed that even if the cell death mode in p53
-/-
 cells was apoptosis, they displayed 
features of necrotic morphology and was further characterized by release of LDH. We next 
questioned if this slow pace apoptosis can force p53
-/-
 cells to die in other ways. Co-
treatment with zVAD-fmk, uridine and Trolox abrogated the LDH release. However, 
formation of mitochondrial ROS was caspase-independent and thus may serve to mediate 
necrotic features. In reverse, 5-FU co-treatment with Trolox did not affect caspase 
processing. We also ruled out the programmed necrosis due to the absence of mitochondrial 
AIF release which can be invoked by Ca
2+
 overload
181
. In conclusion, under the 
experimental conditions used, formation of mitochondrial ROS did not contribute to overall 
caspase processing in p53
-/-
 cells but did contribute to release of LDH. 
It has been suggested that p53 can both induce and suppress autophagy depending on the 
type of stress
182,183
. In paper III, we tested whether there is a cross-talk between autophagy 
and apoptosis upon 5-FU treatment. We observed signs of autophagy deregulation in p53
-/-
 
cells. Inhibition of apoptosis at DISC or mitochondria level, on the other hand, did not 
interfere with 5-FU-induced autophagy. In reverse, downregulation of autophagy related 
proteins by siRNA did not reduce 5-FU generated apoptosis. However, CQ and 5-FU co-
treatment caused a prominent decrease in the apoptotic response at the caspase-8 level 
without altering the cFLIP isoforms thus positioning the effect upstream of DISC 
formation. As 5-FU-induced apoptosis was maintained in cells where key autophagy factors 
had been targeted by siRNA, we concluded that the effect of CQ is independent from 
autophagy. Moreover, CQ as a single agent increased p53 and DR5 protein levels without 
any apparent induction of cell death. At the time, we assumed this to be an effect of a 
dramatic change in receptor localization. Related to this observation, Park et al. reported 
that CQ can up-regulate DR5 mRNA levels via reduction in the E3 ligase of DR5
184
.  
However, CQ treatment did not alter the levels of DR5 in the plasma membrane, nor did it 
alter TRAIL induced apoptosis, indicating that the receptor can be activated by at least two 
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different mechanisms. Accordingly, we speculated that there can be a functional link 
between apoptosis and lysosome functions, since we observed that CQ treatment led to the 
accumulation of DR5 in lysosomes and autophagosomes. Akazawa et al. showed that 
internalization of DR5 promotes lysosomal permeabilization and apoptosis
185
. However, 
co-treatment with cathepsin inhibitors rather promoted the 5-FU toxicity through p53 
stabilization. Likewise, co-treatment with brefeldin A (BFA) increased PARP cleavage 
upon TRAIL-induced apoptosis but not upon 5-FU treatment, supporting that inhibition of 
ER to Golgi transport affected TRAIL- and 5-FU-induced apoptosis differently. 
Cholesterol is an important component for membrane integrity, signal transduction and 
lipid raft formation, the latter has been associated with DR activation and formation of the 
DISC
186
. Indeed, inhibition of cholesterol trafficking, causing an increase in intracellular 
levels of soluble cholesterol, served to verify that 5-FU induced apoptosis requires 
cytoplasmic transportation of DR5. 
MSI and components of the MMR system have been investigated as predictive and 
prognostic markers. Results of retrospective studies and meta-analyses suggested that 
patients with a deficient MMR system had better prognosis compared to those with an 
intact MMR system
91,93,187,188
. Investigations of MMR deficiency and resistance to 5-FU 
have presented conflicting results which can be due to analysis of different CRC stages 
between studies
117
. HCT116 is a MLH1 deficient cell line which can affect the sensitivity to 
5-FU. However, we did not see any difference in generated apoptotic markers though 
Meyers et al. showed that reintroduction of MLH1 sensitized HCT116 cells to 5-FU (Fig. 
4B)
189
. The disparity of the results can be an outcome of varying drug concentrations, 
exposure times, and exposure schedules. Clinical studies have also shown that 5-FU 
toxicity may vary between treatment regimens
136
. 
The TS enzyme has two binding sites; one for the nucleotide and one for CH2THF. 
Irreversible binding of FdUMP to TS together with CH2THF results in a stable ternary 
complex leading to depletion of cellular thymidine pools and DNA damage
139
. In clinics, 
leucovorin is used in combination with 5-FU to increase the toxicity and drug 
response
139,150
. Leucovorin can stabilize the ternary complex by increasing the intracellular 
levels of reduced folate. To investigate the link between DNA and RNA damage and 5-FU-
mediated apoptosis, we treated the cell together with leucovorin, uracil or thymidine. Co-
treatment of leucovorin and thymidine together with 5-FU did not increase the apoptotic 
response whereas addition of excess uridine rescued the cells regardless of p53 status. 
Therefore, we speculated that 5-FU is not exerting its effect through TS inhibition in some 
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tumor cell lines. In support to this, MLH1 reintroduced HCT116 cells had the same 
sensitivity to 5-FU as their MLH1-deficient parental cell line (Fig. 4B). In addition, 
inhibition of caspase activity abolished the formation of γH2AX and PAR which are 
regarded as DNA damage markers, indicating that DNA damage is a consequence of 
apoptosis and not vice versa. In fact, ATM inhibition in p53 wt as well as PARP1 inhibition 
in the absence of p53 increased the 5-FU toxicity, indicating that modulation of DNA repair 
systems can generate a synergistic effect with 5-FU-induced RNA stress. 
Taken together, we concluded that in our experimental settings the effects of 5-FU is more 
directed to RNA rather than to DNA damage. In agreement with our findings, 5-FU and its 
metabolites have shown to affect proteins related to RNA metabolism. Moreover, 5-FU 
metabolites have been implicated in the downregulation of ribosomal proteins (Fig. 5)
190
. 
 
FIGURE 4. TRAIL sensitizes HCT116 cells to 5-FU (A) and presence of the MLH1 
protein does not affect drug-induced apoptosis (B). 
HCT116 cells were either treated with 1-10 ng/mL TRAIL or 384 µM 5-FU alone or with combination of 
both for 16 h. p53, processing of PARP and caspase-8 were analyzed by western blot (4A). HCT116 wt and 
HCT116 MLH1
+/+
 cells were treated with 768 µM 5-FU for 24 h and PARP, p53, MLH1 were analyzed by 
western blot (4B). GAPDH served as loading control (Fig. 4A-4B). 
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7. CONCLUSION 
5-FU-induced apoptosis, in the human colon carcinoma cell line HCT116, depends on p53-
facilitated formation of DR-DISCs. This process is, at least partly, regulated by an increase 
in intracellular Ca
2+ 
levels via L-type channels and successive Ca
2+
-calmodulin-kinase 
regulated phosphorylation of at least three p53 serine phosphorylation sites (S15, S33, 
S37). Mutation of the serine 15 phosphorylation site significantly reduces the apoptotic 
response to 5-FU. 
The absence of p53 results in mitochondrial ROS formation, necrotic morphology and 
disruptions in autophagic induction. In addition, silencing of PARP-1 function sensitizes 
p53-deficient cells to 5-FU. 
5-FU induces primarily RNA stress which involves a TRAIL-DISC-dependent apoptosis 
axis facilitated by p53. 
Disruption of lysosomal function with chloroquine reduces the levels of apoptotic markers 
in 5-FU treated cells and leads to accumulation of DR5 in lysosomes and autophagosomes. 
Based on these findings, we disclosed that activation of DR5 is regulated by separate 
mechanisms in TRAIL- and 5-FU-induced apoptosis and that correct trafficking of the 
receptor is important for 5-FU- but not TRAIL-mediated tumor cell elimination. 
 
 
 
 
 
 
 
 
 
 
 44 
8. SIGNIFICANCE OF THE STUDY 
5-FU has been the mainstay of CRC treatment for over 50 years. However, due to the 
frequent occurrence of p53 mutations, response rates for 5-FU in advanced CRC are 
modest. Although combinatorial treatments have improved survival rates, there is still a 
need for new therapeutic strategies potent enough to compensate or bypass cell death 
defects and improve disease prognosis. The data relating to mechanisms of 5-FU-mediated 
RNA stress and death receptor activation that are presented in this thesis will hopefully 
contribute to a better molecular understanding of drug toxicity, which is of the utmost 
importance for the development of future treatment approaches. 
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9. FUTURE PERSPECTIVES 
The new mechanisms for p53 and DR5 activations indicated in paper I-II and III raise 
questions that may be addressed in future scientific projects. 
1. With respect to DR5, how important are the processes of lysosomal exocytosis and 
intracellular receptor transport for oligomerization and activation? 
We noticed that lysosomal accumulation of death receptors is a consequence of CQ or Baf 
A treatments. As we believe that a general membrane and receptor protein migration route, 
important for DR activation, occurs through lysosomes, our aim is to analyze the role of 
lysosomal exocytosis (LE) in DR activation. Exocytosis of secretory lysosomes is known to 
be present in all cell types and is important for cellular processes such as membrane 
remodeling and secretion. Quantification of LE occurring in response to DR activating 
toxicants will be accomplished through preloading (pinocytosis) of the cells with FITC-
dextran. Loss of the dextran from the cells over time in control and treated cells will then be 
monitored by FACS. DR oligomerization/activation analysis will be accomplished by SDS-
PAGE under non-reducing conditions. Compared with synaptic vesicle exocytosis, the 
molecular mechanisms underlying lysosomal exocytosis are much less understood. 
However, distinct sets of exocytosis machinery are employed, that will be used to 
specifically reduce LE in our experimental settings to further analyze the effect on DR 
activation and apoptosis. 
2. With respect to calmodulin and post-translational modifications of p53, what is the role 
of Ca
2+
 in DR activation mechanisms? 
The main purpose of this project is to define the molecular map indicated in paper I, leading 
from cytoplasmic Ca
2+
 influx via calmodulin to p53 phospho-activation, DR5 dimerization 
and apoptosis. The goal is to identify global phosphorylation changes between proteomes 
isolated from control cells, 5-FU-treated cells and treated cells where calmodulin has been 
silenced by means of RNAi. This will be accomplished by 2D DIGE (two-dimensional 
difference gel electrophoresis) followed by phosphorylated protein profiling. The 
experimental set up enables identification of phosphorylation events in general but also 
those specifically regulated by calmodulin. 
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daha da renklendirdiğiniz için, kuzenlerim, Nebiş ve Fahriş’e dostlukları için ve biricik 
Dedem´e sevgisi için çok teşekkürler. 
Thank you, 
Birce Akpinar 
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